<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recombinant human growth hormone (hrGH) has been used for treatment of growth hormone deficient children over 20 years and it can be considered to have an excellent safety profile </plain></SENT>
<SENT sid="1" pm="."><plain>The main international surveys show few adverse drug reactions reported, specially in idiopathic <z:hpo ids='HP_0000824'>growth hormone deficiency</z:hpo> and in idiopathic <z:hpo ids='HP_0004322'>short stature</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>With regard to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence, it seems that there is no greater risk with hrGH treatment in comparison to general population </plain></SENT>
<SENT sid="3" pm="."><plain>The idiopathic intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> is a rare condition, but its incidence is higher in patients with <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The adverse events are rare in patients treated with hrGH, but these patients should be carefully monitored, specially those with pharmacologycal doses or with another clinical condition of greater risk </plain></SENT>
</text></document>